Table 2.
Surgical treatment, demographic, and pathologic data.
| TIR 3A (n = 29) | TIR 3B (n = 90) | p value | |
|---|---|---|---|
| TIRADS score | |||
| 3, 4a, 4b (low-intermediate risk) | 26 | 76 | |
| Benign/malignant | 22/4 | 57/19 | |
| 4c, 5 (high risk) | 3♦ | 14♦ | |
| Benign/malignant | 2/1 | 5/9 | |
|
| |||
| Nodule major diameter, mm (range)∗ | 23.4 ± 14 (4–60) | 29 ± 18 (4–80) | |
|
| |||
| Type of surgery | |||
| HT | 10 | 37 | |
| TT | 19 | 53 | |
|
| |||
| Reasons for TT | |||
| Bilateral goiter | 12 | 28 | |
| Autoimmune thyroid disease | 4 | 5 | |
| Nodule growing in size | 3 | 7 | |
| BRAF/RAS mutation | 9 | 12 | |
| Prior head & neck irradiation | 0 | 0 | |
| Family history of thyroid cancer | 0 | 1 | |
|
| |||
| Completion thyroidectomy | 0 (0%) | 4 (10.8%) | 0.56 |
|
| |||
| Malignancy | 5 (17.2%) | 28 (31.1%) | 0.16 |
| pT1a | 4 | 17¶ | |
| pT1b | 1 | 3 | |
| pT2 | 0 | 5 | |
| pT3 | 0 | 3 | |
|
| |||
| Multifocality/TTs for cancer | 1/4 (25%) | 5/26 (19.2%) | Ns |
| Unilobar | 0 | 0 | |
| Bilobar | 1 | 5 | |
|
| |||
| Extrathyroid invasion | 0 | 2 (7.1%) | Ns |
|
| |||
| Vascular invasion | 0 | 1 (3.6%) | Ns |
|
| |||
| Aggressive variants | 0 | 0 | — |
|
| |||
| Lymph node metastases/lymph node dissections | 1/1 | 0/2 | — |
|
| |||
| Morphology | |||
| Taller than wide | 4 | 17 | |
| Oval/round shape | 25 | 73 | |
|
| |||
| Margins | |||
| Irregular | 3 | 5 | |
| Regular | 26 | 85 | |
|
| |||
| Microcalcifications | |||
| Yes | 5 | 12 | |
| No | 24 | 78 | |
|
| |||
| Echogenicity | |||
| Hypoechogen | 6 | 44 | |
| Nonhypoechogen | 23 | 46 | |
|
| |||
| Echostructure | |||
| Solid | 21 | 77 | |
| Mixed | 8 | 13 | |
Note. Data are presented as mean ± SD where applicable. TT, total thyroidectomy; HT, hemithyroidectomy; ns, nonsignificant. ♦0 cases of TIRADS 5 reported. ∗in bilateral goiter, size of the dominant nodule. ¶ one case of benignity of TIR3B lesion and coexistent occult PTMC in the controlateral lobe.